
Release date: 2026-01-15 16:37:44 Article From: Lucius Laos Recommended: 95
Pralsetinib is indicated for the treatment of patients with metastatic (spread) non-small cell lung cancer (NSCLC) whose tumors harbor a RET fusion-positive gene.
Currently, Pralsetinib manufactured by Lucius Pharmaceuticals is available in only one specification: each box contains 120 capsules, with a dosage of 100 mg per capsule. This specification serves as the current standard packaging and is suitable for a full course of treatment.
The specific price of the medicine is affected by various factors including the purchasing region, medical insurance policies, procurement channels and current market activities, hence no unified selling price has been set. For real-time pricing, purchasing procedures or medication consultation, please scan the official QR code on the product homepage to contact our customer service team directly. Our customer service staff will provide you with detailed cost explanations and purchasing guidance.
1. Medications used to treat cancer are highly potent and may cause numerous side effects. Before receiving this medicine, ensure that you understand all its potential risks and benefits. Close collaboration with your physician during the treatment period is of great importance.
2. Take this medicine strictly in accordance with your doctor’s instructions. Do not take a larger dose than prescribed, do not take it more frequently, and do not take it for a longer duration than recommended. Otherwise, the risk of side effects may increase.
3. A patient information leaflet is provided with this medicine. It is essential to read and understand the information contained therein. If you have any questions or uncertainties, be sure to consult your doctor.
4. Swallow the capsules whole. Do not crush, open or chew them.
5. It is advisable to take this medicine on an empty stomach. Avoid eating for at least 2 hours before administration and at least 1 hour after administration.
1. Dosage of this medicine may vary among different patients. Follow your doctor’s orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not adjust it unless instructed to do so by your doctor.
2. The amount of medicine you take depends on the strength of the medicine. In addition, the frequency of daily administration, the interval between doses and the duration of treatment depend on the medical condition for which you are being treated.
3. For non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC) and thyroid cancer:
( ) Adults: 400 mg once daily. The doctor may adjust the dosage based on your individual needs and tolerance.
(2) Pediatric patients: The usage and dosage must be determined by the doctor.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5522024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3012025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643